Alto Neuroscience, Inc.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on developing novel treatments for psychiatric and neurological disorders. Its pipeline includes several drug candidates targeting conditions such as bipolar depression, major depressive disorder (MDD), cognitive impairment associated with schizophrenia, and Parkinson's disease. Key programs include ALTO-100, a Phase 2b candidate for bipolar depression; ALTO-300, a melatonergic agonist and serotonergic antagonist in Phase 2b for MDD; ALTO-101, a PDE4 inhibitor in Phase 2 for cognitive impairment in schizophrenia; ALTO-203, a histamine H3 receptor inverse agonist in Phase 2 for MDD with anhedonia; ALTO-202, a GluN2B antagonist in Phase 1 for MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant for Parkinson's disease. The company operates in the biotechnology industry within the healthcare sector.

Alto Neuroscience, Inc. is listed on the New York Stock Exchange (NYSE) under the ticker symbol ANRO. The company's financial reporting and stock trading are conducted in US Dollars (USD), reflecting its primary operations in the United States. As a US-based company, it adheres to the regulatory standards of the NYSE and the Securities and Exchange Commission (SEC).

Alto Neuroscience operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on researching and developing drug candidates for mental health and neurological conditions. Biotechnology companies like Alto use biological processes and molecular biology to create therapies, often targeting unmet medical needs in areas such as depression, schizophrenia, and Parkinson's disease.

Alto Neuroscience is headquartered in Mountain View, California, United States. The company was incorporated in 2019, making it a relatively young player in the biotechnology space. Its location in Silicon Valley provides access to a rich ecosystem of life sciences talent and venture capital. The company's pipeline reflects a focus on precision psychiatry, aiming to match patients with treatments based on biomarkers and symptom profiles.